481 related articles for article (PubMed ID: 17207090)
1. Immunohistochemical analysis of Omi/HtrA2 expression in prostate cancer and benign prostatic hyperplasia.
Hu XY; Xu YM; Chen XC; Ping H; Chen ZH; Zeng FQ
APMIS; 2006 Dec; 114(12):893-8. PubMed ID: 17207090
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical analysis of Omi/HtrA2 expression in prostate cancer and benign prostatic hyperplasia.
Hu X; Chen X; Ping H; Chen Z; Zeng F; Lu G
J Huazhong Univ Sci Technolog Med Sci; 2005; 25(6):671-3. PubMed ID: 16696322
[TBL] [Abstract][Full Text] [Related]
3. Mitochondrial protease Omi/HtrA2 enhances caspase activation through multiple pathways.
Suzuki Y; Takahashi-Niki K; Akagi T; Hashikawa T; Takahashi R
Cell Death Differ; 2004 Feb; 11(2):208-16. PubMed ID: 14605674
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical analysis of Omi/HtrA2 expression in stomach cancer.
Lee SH; Lee JW; Kim HS; Kim SY; Park WS; Kim SH; Lee JY; Yoo NJ
APMIS; 2003 May; 111(5):586-90. PubMed ID: 12887511
[TBL] [Abstract][Full Text] [Related]
5. Role of Omi/HtrA2 in apoptotic cell death after myocardial ischemia and reperfusion.
Liu HR; Gao E; Hu A; Tao L; Qu Y; Most P; Koch WJ; Christopher TA; Lopez BL; Alnemri ES; Zervos AS; Ma XL
Circulation; 2005 Jan; 111(1):90-6. PubMed ID: 15611365
[TBL] [Abstract][Full Text] [Related]
6. The serine protease Omi/HtrA2 is involved in XIAP cleavage and in neuronal cell death following focal cerebral ischemia/reperfusion.
Althaus J; Siegelin MD; Dehghani F; Cilenti L; Zervos AS; Rami A
Neurochem Int; 2007 Jan; 50(1):172-80. PubMed ID: 16978742
[TBL] [Abstract][Full Text] [Related]
7. Caspase 3 expression in benign prostatic hyperplasia and prostate carcinoma.
O'Neill AJ; Boran SA; O'Keane C; Coffey RN; Hegarty NJ; Hegarty P; Gaffney EF; Fitzpatrick JM; Watson RW
Prostate; 2001 May; 47(3):183-8. PubMed ID: 11351347
[TBL] [Abstract][Full Text] [Related]
8. Loss of caspase-1 and caspase-3 protein expression in human prostate cancer.
Winter RN; Kramer A; Borkowski A; Kyprianou N
Cancer Res; 2001 Feb; 61(3):1227-32. PubMed ID: 11221855
[TBL] [Abstract][Full Text] [Related]
9. Regulation of HtrA2/Omi by X-linked inhibitor of apoptosis protein in chemoresistance in human ovarian cancer cells.
Yang X; Xing H; Gao Q; Chen G; Lu Y; Wang S; Ma D
Gynecol Oncol; 2005 May; 97(2):413-21. PubMed ID: 15863139
[TBL] [Abstract][Full Text] [Related]
10. Transgenic mice with neuron-specific overexpression of HtrA2/Omi suggest a neuroprotective role for HtrA2/Omi.
Liu MJ; Liu ML; Shen YF; Kim JM; Lee BH; Lee YS; Hong ST
Biochem Biophys Res Commun; 2007 Oct; 362(2):295-300. PubMed ID: 17707776
[TBL] [Abstract][Full Text] [Related]
11. Expression, localization and activity of neutral endopeptidase in cultured cells of benign prostatic hyperplasia and prostate cancer.
Albrecht M; Gillen S; Wilhelm B; Doroszewicz J; Aumüller G
J Urol; 2002 Jul; 168(1):336-42. PubMed ID: 12050566
[TBL] [Abstract][Full Text] [Related]
12. Structural insights into the pro-apoptotic function of mitochondrial serine protease HtrA2/Omi.
Li W; Srinivasula SM; Chai J; Li P; Wu JW; Zhang Z; Alnemri ES; Shi Y
Nat Struct Biol; 2002 Jun; 9(6):436-41. PubMed ID: 11967569
[TBL] [Abstract][Full Text] [Related]
13. Thrombin receptor expression is upregulated in prostate cancer.
Kaushal V; Kohli M; Dennis RA; Siegel ER; Chiles WW; Mukunyadzi P
Prostate; 2006 Feb; 66(3):273-82. PubMed ID: 16245281
[TBL] [Abstract][Full Text] [Related]
14. The serine protease Omi/HtrA2 is released from mitochondria during apoptosis. Omi interacts with caspase-inhibitor XIAP and induces enhanced caspase activity.
van Loo G; van Gurp M; Depuydt B; Srinivasula SM; Rodriguez I; Alnemri ES; Gevaert K; Vandekerckhove J; Declercq W; Vandenabeele P
Cell Death Differ; 2002 Jan; 9(1):20-6. PubMed ID: 11803371
[TBL] [Abstract][Full Text] [Related]
15. Expression analysis and clinical utility of L-Dopa decarboxylase (DDC) in prostate cancer.
Avgeris M; Koutalellis G; Fragoulis EG; Scorilas A
Clin Biochem; 2008 Oct; 41(14-15):1140-9. PubMed ID: 18586020
[TBL] [Abstract][Full Text] [Related]
16. [Expression and significance of caspase-1 in benign hyperplastic prostate tissues].
Deng CH; Zang ZJ; Sun XZ; Huang XH; Wang H; Wang D; Su SH
Zhonghua Nan Ke Xue; 2005 Nov; 11(11):810-2. PubMed ID: 16333955
[TBL] [Abstract][Full Text] [Related]
17. [Effects of Omi/HtrA2 on expression of anti-apoptotic protein PED/PEA-15 and apoptosis of prostate cancer cell line PC-3].
Hu XY; Chen XC; Zhu ZH; Chen CH; Zeng FQ; Lu GC
Ai Zheng; 2006 Jun; 25(6):677-82. PubMed ID: 16764760
[TBL] [Abstract][Full Text] [Related]
18. Increased expression of NKX3.1 in benign prostatic hyperplasia.
Irer B; Toylu A; Aslan G; Celebi I; Yorukoglu K; Atabey N
Urology; 2009 May; 73(5):1140-4. PubMed ID: 18597829
[TBL] [Abstract][Full Text] [Related]
19. Prostate stem cell antigen mRNA expression in preoperatively negative biopsy specimens predicts subsequent cancer after transurethral resection of the prostate for benign prostatic hyperplasia.
Zhao Z; Liu J; Li S; Shen W
Prostate; 2009 Sep; 69(12):1292-302. PubMed ID: 19462463
[TBL] [Abstract][Full Text] [Related]
20. HtrA2 is up-regulated in the rat testis after experimental cryptorchidism.
Hayashi T; Yoshida S; Yoshinaga A; Ohno R; Ishii N; Yamada T
Int J Urol; 2006 Feb; 13(2):157-64. PubMed ID: 16563141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
